HUTCHMED (China) (HMDCF) Cash from Operations (2018 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Cash from Operations came in at $93.7 million in Q2 2021, up 210.87% year-over-year from $30.1 million in Q2 2020, and up 519.02% quarter-over-quarter from -$22.4 million in Q1 2021.
Analysis
HUTCHMED (China) (HMDCF) Cash from Operations (2018 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Cash from Operations for 4 consecutive years, with $93.7 million the latest figure, recorded in Q2 2021.
- On a quarterly basis, Cash from Operations rose 210.87% year-over-year to $93.7 million in Q2 2021; TTM through Jun 2021 was $99.7 million, a 25.81% increase from a year earlier, with the FY2025 full-year figure at -$64.7 million, down 13109.46% from the prior year.
- Cash from Operations was $93.7 million for Q2 2021 at HUTCHMED (China), up from -$22.4 million in the prior quarter.
- Over five years, Cash from Operations peaked at $93.7 million in Q2 2021 and troughed at -$22.4 million in Q1 2021.
- A 4-year average of $17.8 million and a median of $15.7 million in 2018 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations jumped 10528.89% in 2019 and plunged 1172.4% in 2021, its largest moves.
- Over 4 years, Cash from Operations stood at $13.9 million in 2018, then increased by 24.76% to $17.4 million in 2019, then soared by 73.32% to $30.1 million in 2020, then soared by 210.87% to $93.7 million in 2021.
- The last three Cash from Operations figures came in at $93.7 million (Q2 2021), -$22.4 million (Q1 2021), and $30.1 million (Q2 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.98 Bn | 196.99 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 181.24 Bn | 178.06 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 132.38 Bn | 124.53 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 82.97 Bn | 74.97 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.80 Bn | 49.67 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.09 Bn | 30.78 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 31.34 Bn | 30.05 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn | -270.50 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 93.68 Mn |
| Mar 31, 2021 | -22.36 Mn |
| Jun 30, 2020 | 30.13 Mn |
| Mar 31, 2020 | -1.76 Mn |
| Dec 31, 2019 | 17.39 Mn |
| Sep 30, 2019 | 33.48 Mn |
| Jun 30, 2019 | 1.12 Mn |
| Mar 31, 2019 | 28.92 Mn |
| Dec 31, 2018 | 13.94 Mn |
| Sep 30, 2018 | 315,000.00 |
| Jun 30, 2018 | -12.24 Mn |
| Mar 31, 2018 | 30.84 Mn |